Mesenchymal Stromal Cells Inhibit CD25 Expression Via the MTOR Pathway to Potentiate T-cell Suppression

Overview

Journal Cell Death Dis

Specialties Cell Biology
General Medicine

Date 2017 Feb 24

PMID 28230853

Citations 18

Authors

Hyun Seung Yoo

Kyuheon Lee

Kwangmin Na

Yong Xu Zhang

Hyun-Ja Lim

TacGhee Yi

Sun U Song

Myung-Shin Jeon

Affiliations

Soon will be listed here.

Abstract

Mesenchymal stromal cells (MSCs) are known to suppress T-cell activation and proliferation. Several studies have reported that MSCs suppress CD25 expression in T cells. However, the molecular mechanism underlying MSC-mediated suppression of CD25 expression has not been fully examined. Here, we investigated the mTOR pathway, which is involved in CD25 expression in T cells. We showed that MSCs inhibited CD25 expression, which was restored in the presence of an inducible nitric oxide synthase (iNOS) inhibitor. Since CD25 mRNA expression was not inhibited, we focused on determining whether MSCs modulated components of the mTOR pathway in T cells. MSCs increased the phosphorylation of liver kinase B1 (LKB1) and AMP-activated protein kinase (AMPK) and decreased the phosphorylation of ribosomal protein S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1). In addition, the expression of 4E-BP1 increased dramatically in the presence of MSCs. An mGTP pull-down assay showed increased binding of 4E-BP1 to the 5' cap-binding eukaryotic translation initiation factor 4E (eIF4E) complex in the presence of MSCs, which resulted in inhibition of mRNA translation. Treatment with 4EGI-1, a synthetic inhibitor of mRNA translation, also reduced CD25 expression in T cells. Polysome analysis confirmed decreased CD25 mRNA in the polysome-rich fraction in the presence of MSCs. Taken together, our results showed that nitric oxide, produced by MSCs, inhibits CD25 translation through regulation of the LKB1-AMPK-mTOR pathway to suppress T cells.

Citing Articles

Mesenchymal Stem Cells from Mouse Hair Follicles Inhibit the Development of Type 1 Diabetes.

Micanovic D, Stanisavljevic S, Li H, Koprivica I, Jonic N, Stojanovic I Int J Mol Sci. 2024; 25(11).

PMID: 38892159 PMC: 11172537. DOI: 10.3390/ijms25115974.

Calorie restriction-induced leptin reduction and T-lymphocyte activation in blood and adipose tissue in men with overweight and obesity.

Travers R, Trim W, Motta A, Betts J, Thompson D Int J Obes (Lond). 2024; 48(7):993-1002.

PMID: 38538853 PMC: 11216992. DOI: 10.1038/s41366-024-01513-7.

Amniotic MSC affect CD8 naive polarization toward SLEC/MPEC subsets by down-modulating IL-12Rβ1 and IL-2Rα signaling pathways.

Papait A, Vertua E, Signoroni P, Cargnoni A, Magatti M, Stefani F iScience. 2023; 26(12):108483.

PMID: 38077154 PMC: 10709131. DOI: 10.1016/j.isci.2023.108483.

The aryl hydrocarbon receptor controls mesenchymal stromal cell-mediated immunomodulation via ubiquitination of eukaryotic elongation factor-2 kinase.

Lkhagva-Yondon E, Seo M, Oh Y, Jung J, Jeon E, Na K Cell Death Dis. 2023; 14(12):812.

PMID: 38071243 PMC: 10710493. DOI: 10.1038/s41419-023-06341-7.

Mesenchymal stromal cells for bone trauma, defects, and disease: Considerations for manufacturing, clinical translation, and effective treatments.

Bowles-Welch A, Jimenez A, Stevens H, Frey Rubio D, Kippner L, Yeago C Bone Rep. 2023; 18:101656.

PMID: 37425195 PMC: 10323188. DOI: 10.1016/j.bonr.2023.101656.

References

Chen H, Ji S, Wang H, Yan H, Zhu L, Liu J . Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion. Exp Hematol. 2003; 31(11):1019-25. DOI: 10.1016/s0301-472x(03)00228-5. View

Jung K, Song S, Yi T, Jeon M, Hong S, Zheng H . Human bone marrow-derived clonal mesenchymal stem cells inhibit inflammation and reduce acute pancreatitis in rats. Gastroenterology. 2010; 140(3):998-1008. DOI: 10.1053/j.gastro.2010.11.047. View

Caplan A . Mesenchymal stem cells. J Orthop Res. 1991; 9(5):641-50. DOI: 10.1002/jor.1100090504. View

Thomson A, Turnquist H, Raimondi G . Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009; 9(5):324-37. PMC: 2847476. DOI: 10.1038/nri2546. View

Bottcher M, Hofmann A, Bruns H, Haibach M, Loschinski R, Saul D . Mesenchymal Stromal Cells Disrupt mTOR-Signaling and Aerobic Glycolysis During T-Cell Activation. Stem Cells. 2015; 34(2):516-21. DOI: 10.1002/stem.2234. View

Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S . Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002; 30(1):42-8. DOI: 10.1016/s0301-472x(01)00769-x. View

Na K, Yoo H, Zhang Y, Choi M, Lee K, Yi T . Bone marrow-derived clonal mesenchymal stem cells inhibit ovalbumin-induced atopic dermatitis. Cell Death Dis. 2014; 5:e1345. PMC: 4123091. DOI: 10.1038/cddis.2014.299. View

Ren G, Su J, Zhang L, Zhao X, Ling W, Lhuillie A . Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells. 2009; 27(8):1954-62. DOI: 10.1002/stem.118. View

Wang Y, Chen X, Cao W, Shi Y . Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014; 15(11):1009-16. DOI: 10.1038/ni.3002. View

10.

Gandin V, Sikstrom K, Alain T, Morita M, McLaughlan S, Larsson O . Polysome fractionation and analysis of mammalian translatomes on a genome-wide scale. J Vis Exp. 2014; (87). PMC: 4189431. DOI: 10.3791/51455. View

11.

Chi H . Regulation and function of mTOR signalling in T cell fate decisions. Nat Rev Immunol. 2012; 12(5):325-38. PMC: 3417069. DOI: 10.1038/nri3198. View

12.

Jeon M, Yi T, Lim H, Moon S, Lee M, Kang J . Characterization of mouse clonal mesenchymal stem cell lines established by subfractionation culturing method. World J Stem Cells. 2011; 3(8):70-82. PMC: 3192225. DOI: 10.4252/wjsc.v3.i8.70. View

13.

Blagih J, Coulombe F, Vincent E, Dupuy F, Galicia-Vazquez G, Yurchenko E . The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity. 2015; 42(1):41-54. DOI: 10.1016/j.immuni.2014.12.030. View

14.

Papandreou I, Denko N, Olson M, Van Melckebeke H, Lust S, Tam A . Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood. 2010; 117(4):1311-4. PMC: 3056474. DOI: 10.1182/blood-2010-08-303099. View

15.

Kim H, Imbert J, Leonard W . Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev. 2006; 17(5):349-66. DOI: 10.1016/j.cytogfr.2006.07.003. View

16.

Dulamea A . Mesenchymal stem cells in multiple sclerosis - translation to clinical trials. J Med Life. 2015; 8(1):24-7. PMC: 4397514. View

17.

Laplante M, Sabatini D . mTOR signaling at a glance. J Cell Sci. 2009; 122(Pt 20):3589-94. PMC: 2758797. DOI: 10.1242/jcs.051011. View

18.

Groh M, Maitra B, Szekely E, Koc O . Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol. 2005; 33(8):928-34. DOI: 10.1016/j.exphem.2005.05.002. View

19.

Junghans R, Waldmann T, Landolfi N, Avdalovic N, SCHNEIDER W, Queen C . Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res. 1990; 50(5):1495-502. View

20.

Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M . Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004; 363(9419):1439-41. DOI: 10.1016/S0140-6736(04)16104-7. View